利拉格卢提德在2型儿科家族局部脂质缩症中使用,由LMNA突变引起:一个病例报告
Youran Li1, Ronghua Yu1, Ting Song1
1Department of Gastroenterology, Hepatology and Nutrition, Shanghai Children's Hospital, School of medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.
BMC pediatrics
|July 6, 2025
概括
2型家族局部脂质变 (FPLD2) 是一种遗传性疾病,导致脂肪损失和代谢问题. 利拉格卢提德在患有FPLD2.2的儿科患者中有效控制了血糖和脂质的控制.
科学领域:
- 遗传学 是一个遗传学.
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 2型家族局部脂质缩症 (FPLD2),也称为敦尼根综合征,是一种罕见的遗传疾病.
- 由于LMNA基因突变而导致的选择性皮下脂肪损失,胰岛素抵抗和代谢并发症的特征.
研究的目的:
- 描述一个患有FPLD2的中国家庭的临床表现和治疗.
- 突出利拉格卢提德在FPLD2.2中的代谢并发症管理中的作用.
主要方法:
- 一个14岁女孩患有FPLD2.2的案例报告.
- 对异构性LMNA基因突变 (c.1456 A>G) 的遗传确认.
- 用饮食,甲福明,胰岛素治疗,随后使用利拉格卢提德.
主要成果:
- 该患者出现了特征性的脂肪分布和代谢问题,包括糖尿病和脂质失调症.
- 利拉格卢提德在两个月内实现了令人满意的血糖控制.
- 在家族内观察到可变的FPLD2表现,尽管具有相同的LMNA突变.
结论:
- FPLD2表现出可变的表现力,强调需要仔细诊断.
- 利拉格卢提德在儿科FPLD2患者中显示出作为血糖和脂质控制治疗剂的潜力.
- 对FPLD2代谢并发症的新型治疗策略需要进一步的研究.
相关概念视频
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Insulin: Dosing Regimen and Adverse Effects
265
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
265
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Lipid Absorption
782
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
782
Myasthenia Gravis: Overview and Treatment
2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K


